MOSCOW (MRC) -- Swiss specialty chemicals maker Clariant and U.S. group Huntsman abandoned their USD20 billion merger, notching a win for activist investors who fought the deal for months on the grounds it would destroy shareholder value, said Reuters.
White Tale, the investment vehicle of hedge fund manager Keith Meister and New York-based fund 40 North, had raised its Clariant stake to above 20 percent, Reuters reported on Thursday ahead of the announcement the tie-up was dead. White Tale’s rising stake, coupled with other Clariant shareholders who came out against the deal, left the Swiss company doubtful of mustering the two-thirds support necessary for the merger to go through.
The successful revolt comes amid a wave of investor activism in Switzerland, where Credit Suisse and Nestle both face demands for change. Chief Executive Hariolf Kottmann said Clariant still had options to explore after further talks with White Tale, which had so far not presented the company with an alternative plan.
"To do a merger of equals ... is one option, to make a large transformational transaction is another option, to continue to stand alone is a third option," Kottmann told reporters on a call where he vowed to remain CEO. Some analysts said Clariant could become a bid target, though its shares fell about 5 percent on Friday.
"Clariant is again the No. 1 takeover target," said Baader Helvea analyst Markus Mayer, who said bidders might wait until Clariant’s share price fell further, or to see if White Tale could install management more favorable to a takeover.
The collapse of the merger also poses a challenge for Huntsman’s founding family, which was set to hold a significant stake in the combined entity but could now struggle to play a role in a consolidating industry without losing influence. Clariant and Huntsman in May struck an agreement that would have given Clariant 52 percent of the combined entity, saying the deal would produce around USD400 million in annual cost synergies and create the world’s second-biggest specialty chemicals maker behind Evonik.
In fighting the Huntsman tie-up, Meister and 40 North’s David Winter and David Millstone contended the merger would not deliver enough benefits, while exposing Clariant to Huntsman’s debt and volatile commodity chemicals business. Speculation the deal might fail had been mounting as even supporters sold down their stakes. "I thought it was a fantastic deal," said one investor, who sold out on fears White Tale was gaining the upper hand. "I think White Tale want something more short term."
MRC